Cooley advised London-headquartered, NASDAQ-listed Silence Therapeutics, a global clinical-stage biotechnology company developing precision engineered medicines using its proprietary siRNA technology, on its agreement to be acquired by leading science and technology company Merck KGaA, Darmstadt, Germany, in an all-cash transaction with an equity value of approximately $1.3 billion, subject to the satisfaction of customary closing conditions.